According to iX Biopharma, there were over 5.8 million people in the US with Alzheimer’s disease, which is the most common type of dementia, in 2020. The same number of people experience over 100 million agitation episodes per year.
SGX-listed iX Biopharma has launched a programme to develop a sublingual dexmedetomidine wafer for the treatment of agitation in dementia and other indications.
The programme is part of the company’s strategy to repurpose existing approved drugs using its proprietary WaferiX drug delivery platform technology to target new therapeutic areas with unmet or significant medical needs.
